FILTERS
TOPICS
CritiTech PES partner NanOlogy™ Completes Dose Escalation Portion of Phase 2 Clinical Trial of NanoPac® for Treatment of Prostate Cancer
Intratumoral injection of three concentrations of NanoPac successfully completed across a total of 9 patients Highest concentration of NanoPac continues … Continued
More >NanoPac® Inhalation Treatment of NSCLC in a Nude Rat Orthotopic Lung Cancer Model
Background: NanoPac® is patented submicron particle paclitaxel in stable powder form without coating or carrier agents. In a previous PK study, … Continued
More >Targeted Delivery of Submicron Particle Cancer Chemotherapy: Helping Shift the Immunotherapy Paradigm
NanOlogy™, a clinical-stage pharmaceutical development company, was formed in 2015 to increase the effectiveness and safety of CT through targeted … Continued
More >Pharmacokinetic Profile of Inhaled Submicron Particle Paclitaxel (NanoPac) in a Rodent Model
Inhaled chemotherapeutics may enhance pulmonary drug exposure to malignant lesions in the lung without substantially contributing to systemic toxicities. The … Continued
More >Evaluation of Submicron Particle Docetaxel Directly Injected into Uro-Oncologic Xenografts
Suspensions of submicron particle taxanes (Figure 1) allow for direct administration of high, sustained levels of chemotherapeutics at the site … Continued
More >CritiTech PES partner NanOlogy announces First Patient Enrolled in a Phase 1/2 Clinical Trial of NanoDoce® for Treatment of Bladder Cancer
NanOlogy may offer an alternative treatment option for patients with bladder cancer Investigational drug, NanoDoce, is injected locally into tumor … Continued
More >CritiTech PES partner NanOlogy Named to BioSpace Top 20 Life Science Startups to Watch in 2019
BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* … Continued
More >Wuxi AppTec: Small Molecule Chemotherapy May Play a Big Role in Cancer Immunotherapy
The combination of chemotherapies and immunotherapies highlights the significance of small molecule drug development as an ongoing treatment modality. Although … Continued
More >CritiTech Particle Engineering Solutions Presents at BARDA Industry Day 2019
FOR IMMEDIATE RELEASEOctober 24, 2018 CritiTech Particle Engineering Solutions Presents at BARDA Industry Day 2019 CritiTech Particle Engineering Solutions was … Continued
More >CritiTech Particle Engineering Solutions Launches New Pharmaceutical Spray Drying Business
FOR IMMEDIATE RELEASEMay 30, 2018 LAWRENCE, KS – CritiTech Particle Engineering Solutions, a growing Contract Development Manufacturing Organization (CDMO) and … Continued
More >